Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

109.77 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,463
Open 109.77
Bid (Size) 109.67 (30)
Ask (Size) 110.19 (31)
Prev. Close 109.77
Today's Range 109.77 - 109.77
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.66%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
The investment bank analysts who follow these stocks think they can soar even further, with some caveats. 
Via The Motley Fool
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices. 
Via The Motley Fool
Topics Stocks
Exposures US Equities

Performance

YTD
-3.06%
-3.06%
1 Month
-6.85%
-6.85%
3 Month
-12.73%
-12.73%
6 Month
-13.27%
-13.27%
1 Year
+5.04%
+5.04%

More News

Read More
3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Via Benzinga
Exposures Product Safety
Demystifying Merck & Co: Insights From 8 Analyst Reviews
Via Benzinga
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
Is Merck Stock a Buy?
Via The Motley Fool
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Could Summit Therapeutics Become the Next Merck?
Via The Motley Fool
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
The Covid Era Tech Promises To Reinvent Cancer Treatment
Via Benzinga
Exposures COVID-19
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
Via News Direct
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
From Merck & Co., Inc.
Via Business Wire
2 High-Potential Growth Stocks You Shouldn't Overlook
Via The Motley Fool
Evaxion Biotech Partners With Merck To Expand Vaccine Development
Via Benzinga
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
From Merck & Co., Inc.
Via Business Wire
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Via Benzinga
Exposures Product Safety
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Via Benzinga
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
From Merck & Co., Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.